Valganciclovir

Phase 3

Roche Holding AG (RHHBY)

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

0 competitors in Cytomegalovirus Infections

View Full Landscape

Drug Information

Target Indication

Cytomegalovirus Infections

Clinical Trial

NCT00294515

Last updated: 2/9/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Regulatory Approvals

EMA3/18/1997

Vitrasert Implant

The Vitrasert implant is indicated for the local treatment of cytomegalovirus (CMV) retinitis in patients with acquired immunodeficiency syndrome (AIDS) (See 4.4. Special warnings and special precautions for use).

View on EMA

Drug Science

Mechanism of action & safety profile

Developer

RHHBY

Roche Holding AG

Biotechnology•Europe•NYSE

Related Pipeline

RO7204239Phase 3

Obesity

trastuzumab (Herceptin®)Phase 3

Breast Cancer

mycophenolate mofetil [CellCept]Phase 3

Myasthenia Gravis Generalised

LenvatinibPhase 3

Unresectable Hepatocellular Carcinoma

RO7239361Phase 3

Duchenne Muscular Dystrophy

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts